Phase III Study of S-1 + Cisplatin Compared With Single-Agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix.

Trial Profile

Phase III Study of S-1 + Cisplatin Compared With Single-Agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 02 Jun 2017 Primary endpoint (Overall survival) has been met, as per results published at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results comparing efficacy and safety of S-1 plus Cisplatin with those of Cisplatin alone presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 21 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top